World’s first Intranasal vaccine iNCOVACC gets DCGI approval for Covid booster doses

Tags: Science and Technology

World’s first Intranasal vaccine iNCOVACC gets DCGI approval

Bharat Biotech International Limited (BBIL) has announced on 29 November that the iNCOVACC vaccine has become the world's first intra-nasal vaccine to receive primary series and heterologous booster approval.

Important facts

  • Bharat Biotech International Limited (BBIL) is a global leader in vaccine innovation and developer of vaccines for infectious diseases.

  • Now iNCOVACC (BBV154) can be used in India under restricted use in emergency from the Central Drugs Standard Control Organization (CDSCO) for heterologous booster dose for age above 18 years.

  • This nasal vaccine is the second approved COVID-19 vaccine in India after Biological E's Corbevax, which can be used as a mix-and-match booster shot.

  • iNCOVACC is a recombinant replication deficient adenovirus vectored vaccine with a pre-fusion stabilized SARS-CoV-2 spike protein.

  • iNCOVACC has been specially formulated to allow intranasal delivery via nasal drops.

Please Rate this article, so that we can improve the quality for you -

Date Wise Search